Getting patients started on KESIMPTA® (ofatumumab)
Life with relapsing MS is complicated. Starting treatment shouldn’t be
*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA and is intended to give patients a chance to see if KESIMPTA may be right for them. Contact your Sales Representative to learn more.
†KESIMPTA Sensoready Pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.1
Support that works with your practice
‡Based on prescription data collected from April to September 2023.2
§Coverage data are provided by Managed Markets Insight & Technology and data on file, current as of May 2024.3
||81% of patients with commercial insurance have first-line coverage.4
Learn more about local coverage & patient support, including Alongside™ KESIMPTA
Helpful Resources
Download Brochure with Patient Cases and Clinical Data
Download the KESIMPTA Start Form
Download the KESIMPTA Start Form (Spanish)
See educational content from your peers about KESIMPTA
Visit the KESIMPTA Digital Education Lab
Download Authorization and Appeals Kit
Download Patient Authorization Form
Download Patient Authorization Form (Spanish)
Learn more about which patients may be right for KESIMPTA
HBV, hepatitis B virus; Ig, immunoglobulin; MS, multiple sclerosis.
References: 1. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2023. 3. Data on file. Coverage Change-ESI. Novartis Pharmaceuticals Corp; East Hanover, NJ. May 2024. 4. Data on file. First-line Commercial Coverage. Novartis Pharmaceuticals Corp; East Hanover, NJ. October 2024.